Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIX1-armed oncolytic herpes simplex virus
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
NIX1-armed oncolytic herpes simplex virus is an experimental oncolytic immunotherapy designed to treat primary brain tumors, such as glioblastoma (GBM). It consists of an oncolytic herpes simplex virus (oHSV) engineered to express NIX1, a peptide that interferes with the binding of NOTCH ligands to their receptors. By blocking the NOTCH signaling pathway—a pathway often exploited by GBM stem cells to resist treatment and recruit myeloid-derived suppressor cells (MDSCs)—this therapy aims to suppress tumor regrowth and enhance immune-mediated tumor killing. Preclinical studies in intracranial tumor models have demonstrated that NIX1-armed oHSV can significantly increase therapeutic benefit and induce macrophage migration into the tumor microenvironment.
- Other names
- NIX1-expressing oncolytic herpes simplex virusNIX-1-expressing oncolytic herpes simplex virusNIX 1-expressing oncolytic herpes simplex virus
02
Targets
NOTCH (Neurogenic locus notch homolog protein 3)
Beyond the preview
Go deeper on NIX1-armed oncolytic herpes simplex virus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIX1-armed oncolytic herpes simplex virus.